387 related articles for article (PubMed ID: 18085465)
21. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
[TBL] [Abstract][Full Text] [Related]
22. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
[TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
Deschenes J; Discepola M; Abelson M
Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
[TBL] [Abstract][Full Text] [Related]
24. [A multicenter, double-masked, randomized evaluation of olopatadine 0.2% using the conjunctival allergen challenge model in Japanese patients with allergic conjunctivitis].
Ohno S;
Nippon Ganka Gakkai Zasshi; 2012 Dec; 116(12):1123-9. PubMed ID: 23379201
[TBL] [Abstract][Full Text] [Related]
25. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
26. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
Endre L; Hidasi V
Orv Hetil; 2006 Sep; 147(36):1741-3. PubMed ID: 17087018
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
Abelson MB; Welch DL
Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
Lanier BQ; Abelson MB; Berger WE; Granet DB; D'Arienzo PA; Spangler DL; Kägi MK
Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
Spangler DL; Bensch G; Berdy GJ
Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
[TBL] [Abstract][Full Text] [Related]
31. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
[TBL] [Abstract][Full Text] [Related]
32. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
Abelson MB; Turner D
Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
35. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis.
Khurana S; Sharma N; Agarwal T; Chawla B; Velpandian T; Tandon R; Titiyal JS
Eye Contact Lens; 2010 Jul; 36(4):210-4. PubMed ID: 20531202
[TBL] [Abstract][Full Text] [Related]
36. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
[TBL] [Abstract][Full Text] [Related]
37. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
[TBL] [Abstract][Full Text] [Related]
38. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
Villareal AL; Farley W; Pflugfelder SC
Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
[TBL] [Abstract][Full Text] [Related]
39. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.
Shimura M; Yasuda K; Miyazawa A; Otani T; Nakazawa T
Am J Ophthalmol; 2011 Apr; 151(4):697-702.e2. PubMed ID: 21257151
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.
Kamis U; Ozturk BT; Ozkagnici A; Gunduz K
Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
